首页> 外文期刊>Annals of Clinical and Laboratory Science: Official Journal of the Association of Clinical Scientists >Two novel PEX1 mutations in a patient with Zellweger syndrome: The first Korean case confirmed by biochemical, and molecular evidence
【24h】

Two novel PEX1 mutations in a patient with Zellweger syndrome: The first Korean case confirmed by biochemical, and molecular evidence

机译:Zellweger综合征患者的两个新的PEX1突变:第一例经生化和分子证据证实的韩国病例

获取原文
获取原文并翻译 | 示例
       

摘要

Peroxisome biogenesis disorders (PBD) represent a spectrum of genetic disorders characterized by impaired peroxisome assembly. Zellweger syndrome (ZS) is the most severe form of PBD and is characterized by craniofacial abnormalities, severe hypotonia, neonatal seizures, ocular abnormalities, psychomotor retardation, hepatomegaly and increased levels of very long chain fatty acids (VLCFA). The most common mutation associated with the PBD is PEX1. Here, the first Korean patient with ZS confirmed by clinical, biochemical, and molecular findings is reported. Two novel mutations of the PEX1 gene were identified in the patient with ZS. The patient was a compound heterozygote for c.2034_2035delCA and c.2845C>T mutations of the PEX1 gene. Both mutations are novel findings and were inherited from the patient's parents. In summary, here the first Korean case of ZS is reported that was confirmed by two novel mutations of the PEX1 gene.
机译:过氧化物酶体生物发生障碍(PBD)代表了一系列以过氧化物酶体装配受损为特征的遗传性疾病。 Zellweger综合征(ZS)是最严重的PBD形式,其特征是颅面异常,严重的肌张力低下,新生儿惊厥,眼部异常,精神运动迟缓,肝肿大和超长链脂肪酸(VLCFA)含量增加。与PBD相关的最常见突变是PEX1。在这里,报道了首例通过临床,生化和分子检查结果确诊的韩国ZS患者。 ZS患者中鉴定出两个新的PEX1基因突变。该患者是PEX1基因的c.2034_2035delCA和c.2845C> T突变的复合杂合子。两种突变都是新发现,并且是从患者的父母那里继承的。总之,这里报道了韩国首例ZS病例,该病例已通过PEX1基因的两个新突变得到证实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号